Net Present Value Model: Polivy
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Polivy Drug Details
Polatuzumab vedotin (Polivy / Ropolivy) is a monoclonal antibody, acts as an anti-neoplastic agent. It is produced by mammalian Chinese hamster ovary (CHO) cells. It is formulated as lyophilized powder for solution for intravenous route of administration. It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma that has progressed or returned after at least two prior therapies. Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).Polatuzumab vedotin (RG-7596) is under development for the treatment of hematologic malignancies including Burkitt lymphoma, non-Hodgkin’s lymphoma, primary mediastinal B-cell lymphoma, primary cutaneous DLBCL, High-grade B-cell lymphoma, T-cell/histiocyte-rich large B-cell lymphoma, Non-Hodgkin lymphoma, Hodgkin lymphoma (B-Cell Hodgkin Lymphoma),thymic carcinoma and T-Cell lymphomas, T-cell/histiocyte-rich large-B-cell lymphoma, epstein-barr virus (EBV) + DLBCL, NOS, ALK+ large B-cell lymphoma, relapsed or refractory follicular lymphoma and previously untreated relapsed or refractory diffuse large B-cell lymphoma. The drug candidate is administered intravenously. It is an anti-CD79b antibody-drug conjugate (ADC) composed of the cytotoxic agent monomethyl auristatin E (MMAE) linked to an anti-CD79b monoclonal antibody targeting MMAE to B-cells through CD79b. It was also under development for mantle cell lymphoma and chronic lymphocytic leukemia.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas | |||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.